176 related articles for article (PubMed ID: 11164108)
21. The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells.
Zhou Q; Yao Y; Ericson SG
Int J Hematol; 2004 Jan; 79(1):63-73. PubMed ID: 14979481
[TBL] [Abstract][Full Text] [Related]
22. An increase in MPC-1- and MPC-1-CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005).
Otsuyama K; Asaoku H; Kawano MM
Int J Hematol; 2006 Jan; 83(1):39-43. PubMed ID: 16443550
[TBL] [Abstract][Full Text] [Related]
23. In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells.
Asosingh K; Günthert U; Bakkus MH; De Raeve H; Goes E; Van Riet I; Van Camp B; Vanderkerken K
Cancer Res; 2000 Jun; 60(11):3096-104. PubMed ID: 10850462
[TBL] [Abstract][Full Text] [Related]
24. Sequential maturation stages of monoclonal B lineage cells from blood, spleen, lymph node, and bone marrow from a terminal myeloma patient.
Jensen GS; Mant MJ; Pilarski LM
Am J Hematol; 1992 Nov; 41(3):199-208. PubMed ID: 1384318
[TBL] [Abstract][Full Text] [Related]
25. The role of adhesion molecules in multiple myeloma.
Cook G; Dumbar M; Franklin IM
Acta Haematol; 1997; 97(1-2):81-9. PubMed ID: 8980613
[TBL] [Abstract][Full Text] [Related]
26. A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy.
Bataille R; Robillard N; Pellat-Deceunynck C; Amiot M
Immunol Rev; 2003 Aug; 194():105-11. PubMed ID: 12846811
[TBL] [Abstract][Full Text] [Related]
27. MPC-1-CD49e- immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas.
Fujii R; Ishikawa H; Mahmoud MS; Asaoku H; Kawano MM
Br J Haematol; 1999 Apr; 105(1):131-40. PubMed ID: 10233376
[TBL] [Abstract][Full Text] [Related]
28. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.
Deleu S; Lemaire M; Arts J; Menu E; Van Valckenborgh E; King P; Vande Broek I; De Raeve H; Van Camp B; Croucher P; Vanderkerken K
Leukemia; 2009 Oct; 23(10):1894-903. PubMed ID: 19494837
[TBL] [Abstract][Full Text] [Related]
29. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell.
Billadeau D; Ahmann G; Greipp P; Van Ness B
J Exp Med; 1993 Sep; 178(3):1023-31. PubMed ID: 8350044
[TBL] [Abstract][Full Text] [Related]
30. Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse.
Vanderkerken K; De Greef C; Asosingh K; Arteta B; De Veerman M; Vande Broek I; Van Riet I; Kobayashi M; Smedsrod B; Van Camp B
Br J Cancer; 2000 Feb; 82(4):953-9. PubMed ID: 10732771
[TBL] [Abstract][Full Text] [Related]
31. Growth mechanism of human myeloma cells by interleukin-6.
Kawano MM; Ishikawa H; Tsuyama N; Abroun S; Liu S; Li FJ; Otsuyama K; Zheng X
Int J Hematol; 2002 Aug; 76 Suppl 1():329-33. PubMed ID: 12430875
[TBL] [Abstract][Full Text] [Related]
32. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.
Asosingh K; De Raeve H; de Ridder M; Storme GA; Willems A; Van Riet I; Van Camp B; Vanderkerken K
Haematologica; 2005 Jun; 90(6):810-7. PubMed ID: 15951294
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells.
Hata H; Xiao H; Petrucci MT; Woodliff J; Chang R; Epstein J
Blood; 1993 Jun; 81(12):3357-64. PubMed ID: 8507873
[TBL] [Abstract][Full Text] [Related]
34. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
Pilarski LM; Belch AR
Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
[TBL] [Abstract][Full Text] [Related]
35. Tumor cell heterogeneity in multiple myeloma: antigenic, morphologic, and functional studies of cells from blood and bone marrow.
King MA; Nelson DS
Blood; 1989 May; 73(7):1925-35. PubMed ID: 2785420
[TBL] [Abstract][Full Text] [Related]
36. Homing of the myeloma cell clone.
Vanderkerken K; Van Camp B; De Greef C; Vande Broek I; Asosingh K; Van Riet I
Acta Oncol; 2000; 39(7):771-6. PubMed ID: 11145431
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules.
Ishikawa H; Tsuyama N; Kawano MM
Int J Hematol; 2003 Aug; 78(2):95-105. PubMed ID: 12953802
[TBL] [Abstract][Full Text] [Related]
38. Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma.
Xu L; Mohammad KS; Wu H; Crean C; Poteat B; Cheng Y; Cardoso AA; Machal C; Hanenberg H; Abonour R; Kacena MA; Chirgwin J; Suvannasankha A; Srour EF
Cancer Res; 2016 Dec; 76(23):6901-6910. PubMed ID: 27634757
[TBL] [Abstract][Full Text] [Related]
39. Purging of myeloma cells using all-trans retinoic acid in a mouse model.
Henry JM; Morley AA; Sykes PJ
Exp Hematol; 2001 Mar; 29(3):315-21. PubMed ID: 11274759
[TBL] [Abstract][Full Text] [Related]
40. Phenotypic characterization of the human myeloma cell growth fraction.
Robillard N; Pellat-Deceunynck C; Bataille R
Blood; 2005 Jun; 105(12):4845-8. PubMed ID: 15741217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
